Testing effectiveness (Phase 2)Ended earlyNCT05921760
What this trial is testing
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Who this might be right for
IDH1-mutant Cholangiocarcinoma
Servier Bio-Innovation LLC 7